Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ABT-530 Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

NCT03069365
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
La Jolla, California • Pasadena, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

NCT03212521
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

NCT04903626
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir (GLE/PIB)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

NCT02966795
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

NCT02442258
View directory record Official record
Conditions
Renal Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

NCT02939989
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
8
States / cities
Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 3 Interventional Results available

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

NCT03089944
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

NCT02441283
View directory record Official record
Conditions
Hepatitis C
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
20
States / cities
Dothan, Alabama • Bakersfield, California • Coronado, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 3, 2026, 2:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 3, 2026, 2:36 PM EDT